...
首页> 外文期刊>Biological psychiatry >(?)-P7C3-S243 Protects a Rat Model of Alzheimer’s Disease From Neuropsychiatric Deficits and Neurodegeneration Without Altering Amyloid Deposition or Reactive Glia
【24h】

(?)-P7C3-S243 Protects a Rat Model of Alzheimer’s Disease From Neuropsychiatric Deficits and Neurodegeneration Without Altering Amyloid Deposition or Reactive Glia

机译:(?) - P7C3-S243保护来自神经精神缺陷和神经变性的阿尔茨海默病的大鼠模型,而不改变淀粉样蛋白沉积或反应性胶质胶质

获取原文
获取原文并翻译 | 示例

摘要

BackgroundIn addition to cognitive deficits, Alzheimer’s disease (AD) is associated with other neuropsychiatric symptoms, including severe depression. Indeed, depression often precedes cognitive deficits in patients with AD. Unfortunately, the field has seen only minimal therapeutic advances, underscoring the critical need for new treatments. P7C3 aminopropyl carbazoles promote neuronal survival by enhancing nicotinamide adenine dinucleotide flux in injured neurons. Neuroprotection with P7C3 compounds has been demonstrated in preclinical models of neurodegeneration by virtue of promoting neuronal survival independently of early disease-specific pathology, resulting in protection from cognitive deficits and depressive-like behavior. We hypothesize that P7C3 compounds might be uniquely applicable to patients with AD, given the comorbid presentation of depression and cognitive deficits. MethodsAging male and female wild-type and TgF344-AD rats, a well-characterized preclinical AD model, were administered (?)-P7C3-S243 daily for 9 and 18 months, beginning at 6 months of age. Behavioral phenotypes related to cognition and depression were assessed at 15 and 24 months, and brain pathology and biochemistry were assessed at 24 months. Results(?)-P7C3-S243 safely protected aging male and female wild-type and TgF344-AD rats from cognitive deficits and depressive-like behavior. Depressive-like behavior occurred earlier than cognitive deficits in TgF344-AD rats, consistent with AD in many patients. Treatment with (?)-P7C3-S243 blocked neurodegeneration in TgF344-AD rats, without altering amyloid deposition or indicators of neuroinflammation. ConclusionsNeuronal cell death–specific treatment approaches, such as P7C3 compounds, may represent a new treatment approach for patients experiencing the combination of cognitive deficits and depression associated with AD.
机译:背景包括与认知赤字,阿尔茨海默病(AD)与其他神经精神症状有关,包括严重抑郁症。实际上,抑郁症通常先在广告患者中缺乏认知缺陷。不幸的是,该领域只有最小的治疗性进展,强调了对新治疗的关键需求。 P7C3氨基丙基咔唑通过在损伤神经元中加强烟酰胺腺嘌呤二核苷酸通量来促进神经元生存。通过独立于早期疾病特异性病理学促进神经元生存,促进神经元的临床前模型,在神经元的临床前模型中证明了NeuroProtection的神经保护作用,导致保护认知缺陷和抑郁样行为。考虑到抑郁和认知缺陷的合并呈现,我们假设P7C3化合物可能是独特适用于AD患者的患者。含有雄性和雌性野生型和TGF344-AD大鼠,是一种特异的临床前广告模型,每日施用(?) - P7C3-S243,每天6个月,从6个月开始。与认知和抑郁有关的行为表型在15和24个月评估,脑病理和生物化学在24个月内进行评估。结果(?) - P7C3-S243安全保护老化男性和女性野生型和TGF344-AD大鼠,来自认知缺陷和抑郁的行为。类似于TGF344-AD大鼠的认知缺陷发生的抑郁样行为,与许多患者中的广告一致。用(α) - P7C3-S243在TGF344-AD大鼠中阻断神经变性,而不改变淀粉样蛋白沉积或神经引发的指标。结论愈合细胞死亡特异性治疗方法,如P7C3化合物,可用于患者的新治疗方法,用于经历与广告相关的认知缺陷和抑郁症组合的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号